Results · Apr-Jun 2026
Glenmark Pharmaceuticals Q1 FY27 results
Sales grew 23% to ₹4,018 crore from ₹3,264 crore in Apr-Jun 2025.
Operating profit grew 39% to ₹805 crore, an operating margin of 20.0% (up 2.2 points from a year ago).
Net profit grew 928% to ₹483 crore from ₹47 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +7%, net profit +60%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 4,018 | 3,264 | +23% |
| Operating profit (EBITDA) | 804.8 | 580.5 | +39% |
| Operating margin | 20.0% | 17.8% | +2.2 pts |
| Net profit | 482.8 | 47.0 | +928% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.